Fig. 2

The FXR agonist GW4064 inhibited gluconeogenesis and promoted glucose uptake after FK506 treatment in mice for 3 months. a–c Compared with that of the FK506 group, there was an obvious increase in FXR for the FK506 + GW4064 group at the mRNA and protein levels. d Like FXR, SHP1 was downregulated with FK506 treatment and was promoted with FK506 + GW4064 at the mRNA level. e After FK506 was administered at a dose of 1 mg/kg/day to the C57BL/6J mice for 3 months, the mRNA levels of PEPCK obviously increased at the end of the third month compared with those of the control group, and the FXR agonist GW4064 downregulated PEPCK at the mRNA level. f The uptake protein GLUT2 was significantly downregulated at the mRNA level by GW4064 under FK506 treatment. Data are presented as the mean ± SD (n = 7). *P < 0.05 vs. the control group, #P < 0.05 vs. the FK506 group